Newcastle-based NunaBio secures £850k seed funding for DNA synthesis technology

NunaBio Limited, a biotechnology firm based in Newcastle Upon Tyne, has raised an estimated £850k in a seed funding round. The company specializes in enzymatic technology for the synthesis, assembly, and amplification of high-fidelity synthetic DNA. This latest capital injection follows a series of funding activities, including a £250k round in May 2026 and a £1m round in December 2025.

Founded in 2012, NunaBio operates as a next-generation contract development and manufacturing organization. It provides cell-free DNA solutions for applications in gene therapy, vaccine development, and diagnostics. The company technology utilizes disposable, SaaS-controlled hardware units designed to enable DNA production at scales ranging from research to commercial levels. These units are intended to reduce the physical space required compared to traditional DNA synthesis methods.

The March 2026 allotment of £850k adds to a significant period of fundraising for the company. In 2025, NunaBio completed several rounds, including £2.6m in August, £290k in September, and £1m in December. Earlier rounds in 2023 included £1.6m in March and approximately £150k in May.

NunaBio currently employs between 17 and 22 people according to its latest accounts and professional profiles. The company headquarters are located in Newcastle upon Tyne. Its platform is designed to allow researchers and manufacturers to transition from discovery to clinical development without the delays typically associated with traditional DNA production. The company serves the life sciences and pharmaceutical industries by targeting the development of advanced materials and therapies.